mile米乐集团

关于mile米乐集团

致力于纳米抗体创新药物研发

关于mile米乐集团

科研论文

截止现在，mile米乐集团生物研发团队在具有重要影响力的期刊上发表研究论文多篇。

TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer

发表于:J Nanobiotechnology. 2023 Nov 6;21(1):410

查看更多内容

Identification and Characterization of a Novel Nanobody Against Human CTGF to Reveal Its Antifibrotic Effect in an in vitro Model of Liver Fibrosis

发表于:Int J Nanomedicine. 2023 Sep 21;18:5407-5422

查看更多内容

Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma

发表于:Respiratory Research. 2022 Nov 19;23(1):316

查看更多内容

Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein

发表于:Cells. 2022 Oct 24;11(21):3355

查看更多内容

Atomically dispersed Mn boosting photoelectrochemical SARS-CoV-2 spike protein immunosensing on carbon nitride

发表于:Journal of Environmental Chemical Engineering. 2022 Dec;10(6):108697

查看更多内容

Evaluation of SARS-CoV-2-neutralizing Nanobody Using Virus Receptor Binding Domain Administered Model Mice-Research-2022

发表于:Research (Wash D C). 2022 Jul 22;2022:9864089

查看更多内容

总计 24 123 4